scholarly journals Trifluoperazine induced blepharospasm: a case report

2017 ◽  
Vol 4 (3) ◽  
pp. 867
Author(s):  
Indu Dhiman ◽  
Umesh Dhiman ◽  
Tarun Sharma ◽  
Aradhna Sharma
Keyword(s):  
Case Report ◽  
Atypical Antipsychotic ◽  
Antipsychotic Drug ◽  
Unusual Case ◽  
Typical Antipsychotic ◽  
Atypical Antipsychotic Drug ◽  
Drug Induced

We hereby report an unusual case of trifluoperazine (typical antipsychotic drug) induced tardive blephrospasm which was relieved subsequently after dechallenging the drug. Thereafter patient was started with clozapine (atypical antipsychotic drug). This possibility of blepharospasm should always be kept in mind while prescribing trifluoperazine.

ICI 204, 636: A New Atypical Antipsychotic Drug

1996 ◽  
Vol 168 (S29) ◽  
pp. 45-56 ◽  
Author(s):  
Steven R. Hirsch ◽  
Christopher G. G. Link ◽  
Jeffrey M. Goldstein ◽  
Lisa A. Arvanitis
Keyword(s):  
Side Effects ◽  
Atypical Antipsychotic ◽  
Antipsychotic Drug ◽  
Antipsychotic Agents ◽  
Pharmacological Action ◽  
Therapeutic Effects ◽  
Typical Antipsychotic ◽  
Extrapyramidal Side Effects ◽  
Dopaminergic Receptors ◽  
Atypical Antipsychotic Drug

The therapeutic effects of ‘classic’ (typical) antipsychotic agents lie in their ability to block central dopaminergic receptors – a property that is also responsible for the frequent occurrence of undesirable extrapyramidal side-effects (EPS). In contrast to these typical agents, clozapine alone has distinguished itself in humans – by virtue of its enhanced antipsychotic action and lack of concurrent EPS – as an atypical antipsychotic. However, the use of clozapine has been limited by the occurrence of agranulocytosis and, to a lesser extent, seizures (Alvir et al, 1993; Haring et al, 1994). The mechanism underpinning the atypical profile of clozapine remains elusive. One hypothesis suggests that it lies in clozapine's higher serotonin 5-HT2: D2 binding ratio, when compared with typical agents – a factor being considered as a predictor of atypicality (Meltzer, this issue; Meltzer et al, 1989). However, an emerging view is that it is not a single pharmacological action, but rather multiple properties that may define an atypical, clozapine-like compound (Lieberman, 1993).

Are Atypical Antipsychotic Drugs also Atypical Antidepressants?

2001 ◽  
Vol 35 (5) ◽  
pp. 631-638 ◽  
Author(s):  
Gordon Parker ◽  
Gordon Parker ◽  
Gin Malhi
Keyword(s):  
Atypical Antipsychotic ◽  
Antipsychotic Drug ◽  
Antipsychotic Drugs ◽  
Case Series ◽  
Antidepressant Activity ◽  
Typical Antipsychotic ◽  
Treatment Resistant ◽  
Melancholic Depression ◽  
Atypical Antipsychotic Drug ◽  
Atypical Antipsychotic Drugs

Objective: To report a case series and review the psychopharmacology of the neuroleptic drugs to suggest that the atypical antipsychotic drugs may have an antidepressant action, at least for those patients with the melancholic subtype. Method: We note the literature suggesting that the older (or typical) antipsychotic drugs were established as having antidepressant activity, describe an open study of some two dozen patients with a treatment-resistant melancholic depression, describe rapid resolution of depression and augmentation benefits associated with commencing an atypical antipsychotic drug in a percentage of subjects, and then review relevant psychopharmacological studies to consider whether there is a rationale for use of antipsychotic drugs to treat depression. Results: Of some two dozen patients treated with an atypical antipsychotic drug, almost immediate improvement was noted in four patients, and evidence of augmentation benefit obtained in another three patients. Conclusions: Impressions from this case series are encouraging. However, as open clinical observational studies are problematic, controlled studies are required to establish whether the atypical antipsychotic drugs have a role in the management of certain expressions of depression, and, in particular, treatment-resistant melancholic depression.

scholarly journals Housing temperature influences atypical antipsychotic drug‐induced bone loss in female C57BL / 6J mice

JBMR Plus ◽  
2021 ◽  
Author(s):  
Roni F. Kunst ◽  
Audrie L. Langlais ◽  
Deborah Barlow ◽  
Karen L. Houseknecht ◽  
Katherine J. Motyl
Keyword(s):  
Bone Loss ◽  
Atypical Antipsychotic ◽  
Antipsychotic Drug ◽  
Atypical Antipsychotic Drug ◽  
Drug Induced ◽  
Housing Temperature

scholarly journals Risperidone induced tardive dyskinesia

2021 ◽  
Vol 10 (2) ◽  
pp. 196
Author(s):  
Elakkya Kolanchinathan ◽  
Dhanya Thirookaran Harichandran ◽  
Sujatha Mangattuvalappil Balakrishnan
Keyword(s):  
Case Report ◽  
Tardive Dyskinesia ◽  
Atypical Antipsychotic ◽  
Antipsychotic Drug ◽  
Male Patient ◽  
Low Dose ◽  
Paranoid Schizophrenia ◽  
Extrapyramidal Symptoms ◽  
Atypical Antipsychotic Drug ◽  
History Of

Risperidone is an atypical antipsychotic drug which has been less likely to produce extrapyramidal symptoms. The aim of this case report is to illustrate that low dose risperidone may cause tardive dyskinesia. A 29 year old male patient with 9 year history of paranoid schizophrenia, developed tardive dyskinesia after receiving risperidone 2 mg for 7 years. He had received small dosages of Haloperidol before the therapy of risperidone for short periods.

Sign in / Sign up

Export Citation Format

Share Document